FLECAINIDE TABLET

Страна: Канада

мова: англійська

Джерело: Health Canada

Активний інгредієнт:

FLECAINIDE ACETATE

Доступна з:

SANIS HEALTH INC

Код атс:

C01BC04

ІПН (Міжнародна Ім'я):

FLECAINIDE

Дозування:

50MG

Фармацевтична форма:

TABLET

Склад:

FLECAINIDE ACETATE 50MG

Адміністрація маршрут:

ORAL

Одиниць в упаковці:

15G/50G

Тип рецепту:

Prescription

Огляд продуктів:

Active ingredient group (AIG) number: 0116696004; AHFS:

Статус Авторизація:

APPROVED

Дата Авторизація:

2023-01-30

Характеристики продукта

PRODUCT MONOGRAPH
PR
FLECAINIDE
FLECAINIDE TABLETS BP
50 MG AND 100 MG (AS FLECAINIDE ACETATE)
ANTIARRHYTHMIC AGENT
Sanis Health Inc.
DATE OF PREPARATION
1 President's Choice Circle
JAN 30, 2023
Brampton, Ontario
L6Y 5S5
SUBMISSION CONTROL NUMBER: 270843
PRODUCT MONOGRAPH
Pr
FLECAINIDE
Flecainide Tablets BP
50 mg and 100 mg (as Flecainide acetate)
Antiarrhythmic Agent
ACTIONS AND CLINICAL PHARMACOLOGY
Flecainide belongs to the membrane stabilizing group of antiarrhythmic
agents; it has
electrophysiologic effects characteristics of the 1C class of the
modified Vaughan-Williams
classification. It also possesses local anesthetic properties.
In single cell preparations from canine cardiac tissues (Purkinje
fibers), flecainide decreased the
rate of rise (V
max
, Phase 0) of the action potential without greatly affecting its
duration; the
duration of the effective refractory period was lengthened and a small
change was observed in
the slope of Phase 4 depolarization. In ventricular muscle, some
lengthening of the action
potential duration has been observed.
In man, flecainide produces a dose-related decrease in intracardiac
conduction in all parts of the
heart with the greatest effect on the His-Purkinje system (H-V
conduction). Effects upon
atrioventricular (AV) nodal conduction time and intra-atrial
conduction times, although present,
are less pronounced than those on ventricular conduction velocity.
Significant effects on
refractory periods were observed only in the ventricle. Sinus node
recovery times (corrected)
following pacing and spontaneous cycle lengths are somewhat increased.
This latter effect may
become significant in patients with sinus node dysfunction (see
WARNINGS). In patients with
accessory AV connections, flecainide has been shown to depress both
anterograde and
retrograde conduction over the bypass tract.
HEMODYNAMICS
Decreases in ejection fraction, consistent with a negative inotropic
effect, have been observed
after a single administration of 200 to 250 mg of flecainide; both
increases and decrea